DJO, a wholly-owned subsidiary of DJO Finance (DJOFL), has completed the acquisition of US-based medical device company Exos for an undisclosed sum.
Exos' commercial products include a thermoformable bracing system, which is comprised of a waterproof, removable, adjustable and reformable solution designed for the treatment of fractures and other injuries requiring stabilisation.
DJO, which is already the distribution partner for Exos, said that the merger will not impact DJOFL's reported net sales.
The merger, however, is expected to increase DJOFL's operating margins and operating income from the sale of Exos products.
The company also indicated that, on a pro forma basis, it does not expect any material changes in DJOFL's ratios of net first lien debt or net total debt to pro forma consolidated earnings before interest, taxes, depreciation, and amortisation (EBITDA).
DJO Global bracing and supports business unit president Steve Ingel said the combination of the company's distribution network and Exos' technology, has enabled DJO to make significant headway in the marketplace.
"We welcome the entire Exos team to our DJO Global family and look forward to working together with them to launch more products incorporating the Exos technology to more customers in more geographies around the world," Ingel said.